1-6 of 6
abemaciclib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Recurrent Genomic Aberrations of D-Type Cyclins Are Therapeutic Targets of CDK4/6 Inhibitors in t(8;21) and MLL -Rearranged Acute Myeloid Leukemia

Hidemasa Matsuo, PhD, Kenichi Yoshida, MD PhD, Kazutaka Fukumura, PhD, Kana Nakatani, Yuki Noguchi, Saho Takasaki, Mina Noura, Yusuke Shiozawa, MD, PhD, Yuichi Shiraishi, PhD, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Ai Okada, Yasuhito Nannya, MD PhD, June Takeda, MD, Hiroo Ueno, MD, Norio Shiba, MD PhD, Genki Yamato, MD PhD, Nobutaka Kiyokawa, MD PhD, Daisuke Tomizawa, MD PhD, Takashi Taga, MD PhD, Akio Tawa, MD PhD, Yasuhide Hayashi, MD PhD, Hiroyuki Mano, MD, PhD, Satoru Miyano, PhD, Yasuhiko Kamikubo, MD, PhD, Seishi Ogawa, MD PhD, Souichi Adachi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2797.
https://doi.org/10.1182/blood-2018-99-111073
Published: 2018
Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1363.
https://doi.org/10.1182/blood-2018-99-116525
Published: 2018
Journal Articles

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, BSc,PhD, Kanak Raina, PhD, Yimin Qian, PhD, Andrew Crew, Dyana T. Saenz, PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, David N Saenz, Craig M Crews, PhD, Kapil N. Bhalla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1265.
https://doi.org/10.1182/blood.V130.Suppl_1.1265.1265
Published: 2017
Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy

Noriyoshi Iriyama, MD PhD, Hirotsugu Hino, Shota Moriya, Masaki Hiramoto, Yoshihiro Hatta, MD PhD, Masami Takei, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4478.
https://doi.org/10.1182/blood.V128.22.4478.4478
Published: 2016
Journal Articles

The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive with Ibrutinib

Luca Fischer, Andrea Schnaiter, MD, Bianca Freysoldt, Markus Irger, Yvonne Zimmermann, Grit Hutter, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5124.
https://doi.org/10.1182/blood.V126.23.5124.5124
Published: 2015
Journal Articles

Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Franck Morschhauser, MD PhD, Kamal Bouabdallah, MD, Stephan Stilgenbauer, MD, Catherine Thieblemont, MD PhD, Martin Wolf, MD, Sophie de Guibert, MD, Florian Zettl, MD, Marjo Hahka-Kemppinen, MD PhD, David Xiaohui Wang, MD PhD, Patrick Brueck, MD, Charles Caldwell, MD, Richard Beckmann, PhD, Lawrence Gelbert, PhD, Damien Cronier, PhD, Ji Lin, PhD, Lily Li, MD, Edward M. Chan, MD, Michael Pfreundschuh, Martin Wilhem, MD, Georg Hess, MD
Journal: Blood
Blood (2014) 124 (21): 3067.
https://doi.org/10.1182/blood.V124.21.3067.3067
Published: 2014